The 2011 Biotech Graveyard

Biotech Graveyard

It's that time of year again; time to visit the biotech graveyard to reflect on the developers whose businesses have in one way or another failed. There's a common theme among many of this year's graveyard companies: most of their problems started in 2009, which was one of the toughest years on record for biotech. (It was also the first year of the biotech graveyard; we said farewell to a record 16 developers that year).

Many of these companies are reminders of how difficult the biotech game is; one failure in the clinic nowadays can ruin a small drug developer, and limited supplies of capital have made some investors extremely conservative with their bets on teams that have faltered with previous R&D programs. Yet what makes this industry difficult also makes it great; success in biotech beats the odds and can improve the lives of patients.

  • Advanced Life Sciences
  • Altair Therapeutics
  • Ambrilia Biopharma
  • ARYx Therapeutics
  • Peptimmune
  • Phenomix Corporation
  • Tolerx
  • Transdel

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.

A Cedars-Sinai team used stem cells to uncover a key mechanism of young onset Parkinson's, as well as a potential remedy—an existing skin treatment.